Allogene Therapeutics, Inc. Income Statement
ALLO|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Allogene Therapeutics, Inc. reported $0 in revenue and $191M in net loss for FY2025. Revenue has declined at a 4.0% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $95.0K | $114.1M | $103.0K | $0 |
| SG&A Expense | $56.8M | $71.7M | $74.1M | $39.4M | $57.5M |
| R&D Expense | $150.2M | $242.9M | $220.2M | $117.3M | $144.5M |
| Operating Income | -$209.3M | -$327.7M | -$180.2M | -$156.6M | -$202.0M |
| Income Tax | $0 | $0 | $0 | $0 | -$331.0K |
| Net Income | -$190.9M | -$327.3M | -$182.1M | -$158.9M | -$184.6M |
| EPS (Basic) | -$1.32 | -$2.09 | -$1.34 | -$2.08 | -$1.83 |
| EPS (Diluted) | -$1.32 | -$2.09 | -$1.34 | -$2.08 | -$1.83 |
| Shares Outstanding | 212.2M | 168.6M | 143.6M | 142.6M | 140.5M |
| Operating Margin | - | -344986.3% | -157.9% | -152068.0% | - |
| Profit Margin | - | -344489.5% | -159.6% | -154268.9% | - |